The Laboratories for Chemical Biology at Karolinska  Institutet (LCBKI) were formally established in 2010 at the Division of Chemical Biology, Department of Medical Biochemistry and Biophysics.  LCBKI is housed in newly built laboratories encompassing ca 500 sq meters of the Science for Life Laboratory and is designed to provide academic researchers on a national level expertise and capabilities within assay development, screening, medicinal chemistry, computational chemistry, and compound library design and development.  The majority of the lab's infratructure was donated to the CBCS initiative from Biovitrum AB, including the Biovitrum Compound Collection, containing over 70,000 high quality screening compounds, many of which are exclusive to LCBKI.  The LCBKI team is comprised of highly experienced researchers from the pharmaceutical industry, with over 100 years of combined experience of small molecule development from pharmaceutical and Biotech companies such as Astra Zeneca, Novo Nordisk, Pharmacia, Biovitrum, Roche, iNovacia and GE Healthcare.

As a major component of Chemical Biology Consortium Sweden, it is the primary aim of LCBKI to assist academic groups in Sweden with the identification, development, and application of small-molecules to aid research leading to greater understanding of fundamental, disease-related biological processes.  By enhancing chemical biology research nationally, LCBKI aims to ultimately strengthen Swedish biomedical and pharmaceutical research sector, providing greater understanding of human biology and better validation of new pharmaceutical targets for the treatment of disease. 

LCBKI currently coordinates collaborations within the fields of assay development, computational chemistry, medicinal chemistry, small molecule screening and novel target deconvolution with over 50 research groups at every major Swedish university.

Feel free to contact one of us for more information on how we can assist you with your project!